Evidence map›Paper›PMID 33319079›Full record

ArticleeNeurologicalSci2021

SQSTM1

Masahisa Nozaki, Asako Otomo, Shun Mitsui, Suzuka Ono, Ryohei Shirakawa, YongPing Chen, Yutaro Hama, Kai Sato, XuePing Chen, Toshiyasu Suzuki and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeurologicalSci, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Masahisa NozakiMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Asako OtomoMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Shun MitsuiMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Suzuka OnoMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Ryohei ShirakawaMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
YongPing ChenDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Yutaro HamaMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Kai SatoMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
XuePing ChenDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Toshiyasu SuzukiDepartment of Anesthesiology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Hui-Fang ShangDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Shinji HadanoMolecular Neuropathobiology Laboratory, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Tokai University · JPSichuan University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are genetically, pathologically and clinically-related progressive neurodegenerative diseases. Thus far, several

Indexed as

ALS, amyotrophic lateral sclerosisAmyotrophic lateral sclerosis (ALS)AutophagyCCCP, carbonyl cyanide 3-chlorophenylhydrazoneCI, complete protease inhibitorCQ, chloroquineDAPI, 4′,6-diamidino-2-phenylindole dihydrochlorideDMEM, Dulbecco's Modified Eagle's mediumDTT, dithiothreitolEBSS, Earle's Balanced Salt SolutionFrontotemporal dementia (FTD)GST, glutathione S-transferaseHA, hemagglutininHRP, horseradish peroxidaseIPTG, isopropyl thio-beta-D-galactosideMAP1LC3/LC3MEF, mouse embryonic fibroblastMND, motor neuron diseaseNGS, normal goat serumPAGE, polyacrylamide gel electrophoresisPBS, phosphate-buffered salinePFA, paraformaldehydePVDF, polyvinylidene difluorideRT, room temperatureSBMA, spinal and bulbar muscular atrophySDS, sodium dodecyl sulfateSQSTM1SQSTM1/p62-bodyWT, wild-type

Identifiers

PMID33319079
PMCPMC7723791
OpenAlexW3109597924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.